Ceritinib
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Anaplastic Thyroid Cancer
Conditions
Metastatic Anaplastic Thyroid Cancer, Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
Trial Timeline
Jun 1, 2015 → Jan 1, 2019
NCT ID
NCT02289144About Ceritinib
Ceritinib is a phase 2 stage product being developed by Novartis for Metastatic Anaplastic Thyroid Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02289144. Target conditions include Metastatic Anaplastic Thyroid Cancer, Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05100134 | Pre-clinical | Active |
| NCT02584933 | Approved | Active |
| NCT02638909 | Phase 2 | Terminated |
| NCT02513667 | Phase 2 | Terminated |
| NCT02289144 | Phase 2 | Withdrawn |
| NCT02343679 | Phase 2 | Withdrawn |
| NCT02299505 | Phase 1 | Completed |
| NCT02336451 | Phase 2 | Completed |
| NCT02186821 | Phase 2 | Terminated |
| NCT01742286 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Anaplastic Thyroid Cancer